Mutation Analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese Patients with Myeloproliferative Neoplasms

Table 2

The relationship between JAK2V617F mutation and age at diagnosis.

	≥60 years 𝑛 = (56)		<60 years 𝑛 = (64)		𝑃 value
	Positive	Negative	Positive	Negative
PV patients	14 (100%)	0	5 (45%)	6	0.003
ET patients	17 (74%)	6	16 (50%)	16	0.098
MF patients	6 (46%)	7	3 (27%)	8	0.423
MPN-u patients	4 (80%)	1	6 (60%)	4	0.6
^∗𝑃 value	0.016		0.471
All patients	41	14	30	34	0.003

𝑃value refers to the comparison of JAK2V617F mutation rate between patients >60 years old and <60 years old within all patients and every subgroup.
^∗𝑃 value refers to the JAK2V617F mutation rate difference between four subgroups in patients >60 years old and patients <60 years old.
MPN: myeloproliferative neoplasms; PV: polycythemia vera; ET: essential thrombocythemia; MF: myelofibrosis; MPN-u: MPN-unclassifiable; CNL: chronic neutrophilic leukemia.